Skip to main navigation
Skip to search
Skip to main content
Bar-Ilan University Home
Help & FAQ
Link opens in a new tab
Search content at Bar-Ilan University
Home
Researchers
Organisations
Research output
Prizes
Student theses
Courses
Activities
Projects
Press/Media
Datasets
Equipment
Oxaliplatine et thérapies ciblées
Translated title of the contribution
:
Oxaliplatin and targeted therapies
Michel Ducreux
, David Malka
, Valérie Boige
Institut Gustave Roussy
Hôpital Paul Brousse
Research output
:
Contribution to journal
›
Review article
›
peer-review
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Oxaliplatin and targeted therapies'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Targeted Therapy
100%
Oxaliplatin
100%
FOLFIRINOX
100%
Colorectal Cancer
33%
Adjuvant Setting
33%
Overall Survival
16%
Tumor
16%
Fluoro
16%
Therapeutic Potential
16%
Chemotherapy
16%
Phase II Trial
16%
Antiangiogenic
16%
Gastrointestinal Tract
16%
Stomach
16%
EGF Receptor
16%
Metastatic Cancer
16%
Bevacizumab
16%
Pyrimidine
16%
Cetuximab
16%
Phase I Study
16%
Biotherapy
16%
Pancreas Cancer
16%
Direct Argument
16%
Gastrointestinal Cancer
16%
GEMOX
16%
Randomized Phase III Trial
16%
Esophagus Cancer
16%
Extremely Rare
16%
Irinotecan-based Chemotherapy
16%
Indirect Arguments
16%
Medicine and Dentistry
Targeted Therapy
100%
Oxaliplatin
100%
Malignant Neoplasm
50%
Colorectal Carcinoma
50%
Chemotherapy
50%
Overall Survival
25%
Metastatic Carcinoma
25%
Epidermal Growth Factor Receptor
25%
Antiangiogenic
25%
Stomach
25%
Irinotecan
25%
Esophagus
25%
Gastrointestinal Cancer
25%
Biological Therapy
25%
Cetuximab
25%
Bevacizumab
25%
Tumor
25%
Oral
25%
Phase III Trials
25%
Pharmacology, Toxicology and Pharmaceutical Science
Oxaliplatin
100%
Malignant Neoplasm
50%
Colorectal Carcinoma
50%
Chemotherapy Regimens
50%
Antiangiogenic
25%
Overall Survival
25%
Bevacizumab
25%
Pyrimidine Derivative
25%
Irinotecan
25%
Digestive System Cancer
25%
Cetuximab
25%
Epidermal Growth Factor Receptor
25%
Phase III Trials
25%
Biochemistry, Genetics and Molecular Biology
Targeted Therapy
100%
Esophagus
25%
Stomach
25%
Overall Survival
25%
Epidermal Growth Factor Receptor
25%
Bevacizumab
25%
Phase III Trials
25%
Cetuximab
25%